BC
GBT

Broadfin Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Broadfin Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-350,000
Closed -$14.4M – 51
2018
Q4 		$14.4M Buy
350,000
+200,000
+133% +$7.49M 1.89% 15
2018
Q3 		$5.7M Buy
+150,000
New +$6.64M 0.84% 35

Other funds holding GBT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital's GBT Position: Q4 2019 in Review

Broadfin Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2019, closing a stake of 177,016 shares — an estimated $8.59M sold.

Broadfin Capital first reported a position in GBT in Q2 2018 and held it in 5 quarters. The position peaked at $20.9M in Q1 2019. 234 funds tracked by Wall St. Rank hold GBT as of Q4 2019.

  • Broadfin Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 177,016 Global Blood Therapeutics, Inc. shares in Q4 2019, an estimated $8.59M.
  • Broadfin Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 5 quarters.
  • Broadfin Capital's Global Blood Therapeutics, Inc. position peaked at $20.9M in Q1 2019.
  • 234 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.